PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277815
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma:
      Experience of Conversion and Salvage Hepatectomy.
PG  - 501-507
AB  - BACKGROUND/AIM: We report the outcomes of sorafenib therapy for advanced
      hepatocellular carcinoma (HCC) in our Department. PATIENTS AND METHODS:
      Thirty-eight patients with unresectable HCC who were administrated sorafenib from
      2009 to 2015 were investigated retrospectively. RESULTS: The 1-year overall
      survival rate was 59.3%. The macroscopic vascular invasion and response rate were
      independent prognostic factors of survival. Surgical resection after sorafenib
      achieved long-term survival in two cases. Case 1: A patient with locally
      unresectable HCC showed significant response induced by sorafenib, which allowed 
      complete surgical resection. This tumor tested positive for FGF4. Case 2: A
      patient with a history of hepatectomy for HCC had multiple distant metastases.
      Most lesions were reduced in size after sorafenib therapy and new lesions in the 
      remnant liver and residual lung metastases were resected. The sorafenib-resistant
      lesions were negative for FGF4. CONCLUSION: Sorafenib combined with surgical
      resection is a feasible option in advanced HCC patients, if sorafenib has been
      effective.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Yoshimoto, Toshiaki
AU  - Yoshimoto T
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Imura, Satoru
AU  - Imura S
AD  - Department of Surgery, Tokushima University, Tokushima, Japan
      [email protected]
FAU - Morine, Yuji
AU  - Morine Y
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Ikemoto, Tetsuya
AU  - Ikemoto T
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Arakawa, Yusuke
AU  - Arakawa Y
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Iwahashi, Shuichi
AU  - Iwahashi S
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Saito, Y U
AU  - Saito YU
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Takasu, Chie
AU  - Takasu C
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Ishikawa, Daichi
AU  - Ishikawa D
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Teraoku, Hiroki
AU  - Teraoku H
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
FAU - Bando, Yoshimi
AU  - Bando Y
AD  - Division of Pathology, Tokushima University Hospital, Tokushima, Japan.
FAU - Shimada, Mitsuo
AU  - Shimada M
AD  - Department of Surgery, Tokushima University, Tokushima, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - Hepatic resection
OT  - conversion
OT  - hepatocellular carcinoma
OT  - sorafenib
OT  - unresectable
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/21 00:00 [received]
PHST- 2017/11/01 00:00 [revised]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/501 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):501-507.